Serotonin 5-HT3 Receptor Antagonists
"Serotonin 5-HT3 Receptor Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that bind to but do not activate SEROTONIN 5-HT3 RECEPTORS, thereby blocking the actions of SEROTONIN or SEROTONIN 5-HT3 RECEPTOR AGONISTS.
Descriptor ID |
D058831
|
MeSH Number(s) |
D27.505.519.625.850.850.300 D27.505.696.577.850.850.300
|
Concept/Terms |
Serotonin 5-HT3 Receptor Antagonists- Serotonin 5-HT3 Receptor Antagonists
- Serotonin 5 HT3 Receptor Antagonists
- 5-HT3 Antagonist
- 5 HT3 Antagonist
- Antagonist, 5-HT3
- 5-HT3 Antagonists
- 5 HT3 Antagonists
- Antagonists, 5-HT3
|
Below are MeSH descriptors whose meaning is more general than "Serotonin 5-HT3 Receptor Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Serotonin 5-HT3 Receptor Antagonists".
This graph shows the total number of publications written about "Serotonin 5-HT3 Receptor Antagonists" by people in this website by year, and whether "Serotonin 5-HT3 Receptor Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2004 | 0 | 1 | 1 |
2008 | 0 | 1 | 1 |
2010 | 0 | 1 | 1 |
2011 | 0 | 2 | 2 |
2016 | 0 | 1 | 1 |
2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Serotonin 5-HT3 Receptor Antagonists" by people in Profiles.
-
Chaudhry IB, Husain MO, Khoso AB, Kiran T, Husain MI, Qurashi I, Rahman RU, Mehmood N, Drake R, Husain N, Deakin B. Beneficial adjunctive effects of the 5HT3 receptor antagonist ondansetron on symptoms, function and cognition in early phase schizophrenia in a double-blind, 2 ? 2 factorial design, randomised controlled comparison with simvastatin. J Psychopharmacol. 2024 Sep; 38(9):818-826.
-
Aapro M, Hesketh PJ, Jordan K, Gralla RJ, Rossi G, Rizzi G, Palmas M. Safety of an Oral Fixed Combination of Netupitant and Palonosetron (NEPA): Pooled Data From the Phase II/III Clinical Program. Oncologist. 2016 Apr; 21(4):494-502.
-
Hesketh PJ, Bosnjak SM, Nikolic V, Rapoport B. Incidence of delayed nausea and vomiting in patients with colorectal cancer receiving irinotecan-based chemotherapy. Support Care Cancer. 2011 Dec; 19(12):2063-6.
-
Hesketh PJ, Sanz-Altamira P, Bushey J, Hesketh AM. Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy. Support Care Cancer. 2012 May; 20(5):1043-7.
-
Hesketh PJ, Warr DG, Street JC, Carides AD. Differential time course of action of 5-HT3 and NK1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC). Support Care Cancer. 2011 Sep; 19(9):1297-302.
-
Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008 Jun 05; 358(23):2482-94.
-
Kris MG, Hesketh PJ, Herrstedt J, Rittenberg C, Einhorn LH, Grunberg S, Koeller J, Olver I, Borjeson S, Ballatori E. Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer. 2005 Feb; 13(2):85-96.